FI120376B - Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi - Google Patents

Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi Download PDF

Info

Publication number
FI120376B
FI120376B FI20075028A FI20075028A FI120376B FI 120376 B FI120376 B FI 120376B FI 20075028 A FI20075028 A FI 20075028A FI 20075028 A FI20075028 A FI 20075028A FI 120376 B FI120376 B FI 120376B
Authority
FI
Finland
Prior art keywords
seq
antigen
peptide
binding
library
Prior art date
Application number
FI20075028A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI20075028L (fi
FI20075028A0 (fi
Inventor
Kalle Saksela
Original Assignee
Next Biomed Technologies Nbt O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Next Biomed Technologies Nbt O filed Critical Next Biomed Technologies Nbt O
Publication of FI20075028A0 publication Critical patent/FI20075028A0/fi
Priority to FI20075028A priority Critical patent/FI120376B/fi
Priority to PCT/FI2008/050012 priority patent/WO2008087254A2/en
Priority to CA002675122A priority patent/CA2675122A1/en
Priority to EP08701712A priority patent/EP2109772A4/en
Priority to CN200880002505A priority patent/CN101646944A/zh
Priority to JP2009545963A priority patent/JP2010516660A/ja
Priority to AU2008206881A priority patent/AU2008206881A1/en
Priority to US12/522,838 priority patent/US20100048407A1/en
Publication of FI20075028L publication Critical patent/FI20075028L/fi
Application granted granted Critical
Publication of FI120376B publication Critical patent/FI120376B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C07K16/1143—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Ecology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI20075028A 2007-01-17 2007-01-17 Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi FI120376B (fi)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FI20075028A FI120376B (fi) 2007-01-17 2007-01-17 Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
CN200880002505A CN101646944A (zh) 2007-01-17 2008-01-17 检测人免疫缺陷病毒的方法
CA002675122A CA2675122A1 (en) 2007-01-17 2008-01-17 Method for detection of human immunodeficiency virus
EP08701712A EP2109772A4 (en) 2007-01-17 2008-01-17 METHOD FOR DETECTING HUMAN IMMUNE DISEASE VIRUS
PCT/FI2008/050012 WO2008087254A2 (en) 2007-01-17 2008-01-17 Method for detection of human immunodeficiency virus
JP2009545963A JP2010516660A (ja) 2007-01-17 2008-01-17 ヒト免疫不全ウイルスの検出方法
AU2008206881A AU2008206881A1 (en) 2007-01-17 2008-01-17 Method for detection of human immunodeficiency virus
US12/522,838 US20100048407A1 (en) 2007-01-17 2008-01-17 Method for detection of human immunodeficiency virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20075028A FI120376B (fi) 2007-01-17 2007-01-17 Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
FI20075028 2007-01-17

Publications (3)

Publication Number Publication Date
FI20075028A0 FI20075028A0 (fi) 2007-01-17
FI20075028L FI20075028L (fi) 2008-07-18
FI120376B true FI120376B (fi) 2009-09-30

Family

ID=37745720

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20075028A FI120376B (fi) 2007-01-17 2007-01-17 Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi

Country Status (8)

Country Link
US (1) US20100048407A1 (enExample)
EP (1) EP2109772A4 (enExample)
JP (1) JP2010516660A (enExample)
CN (1) CN101646944A (enExample)
AU (1) AU2008206881A1 (enExample)
CA (1) CA2675122A1 (enExample)
FI (1) FI120376B (enExample)
WO (1) WO2008087254A2 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO314588B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
US6818392B2 (en) * 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
US6833441B2 (en) * 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers

Also Published As

Publication number Publication date
EP2109772A1 (en) 2009-10-21
US20100048407A1 (en) 2010-02-25
CA2675122A1 (en) 2008-07-24
WO2008087254A8 (en) 2009-07-30
CN101646944A (zh) 2010-02-10
FI20075028L (fi) 2008-07-18
AU2008206881A1 (en) 2008-07-24
WO2008087254A2 (en) 2008-07-24
JP2010516660A (ja) 2010-05-20
FI20075028A0 (fi) 2007-01-17
EP2109772A4 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
KR102229225B1 (ko) 사스-코로나바이러스-2 표면의 스파이크 단백질에 결합하는 사스-코로나바이러스 감염증의 진단용 결합 분자
CN107022027B (zh) Hiv-1广谱中和抗体及其用途
US7049060B2 (en) HCV anti-core monoclonal antibodies
CN104520318B (zh) 针对jc病毒的vp1蛋白的人单克隆抗体
CN117720650B (zh) 抗人呼吸道合胞病毒抗体及其应用
Jayathilake et al. In vitro selection of anti-gliadin single-domain antibodies from a naïve library for cDNA-display mediated immuno-PCR
KR102008609B1 (ko) 지카 바이러스의 비구조단백질 1에 대한 특이 항체를 생산하는 하이브리도마 및 이로부터 생성된 항체, 이의 용도
KR102012123B1 (ko) 뎅기 바이러스 및 지카 바이러스의 비구조단백질 1에 동시에 결합 가능한 항체를 생산하는 하이브리도마 및 이로부터 생성된 항체, 이의 용도
Gazarian et al. Mimotope peptides selected from phage display combinatorial library by serum antibodies of pigs experimentally infected with Taenia solium as leads to developing diagnostic antigens for human neurocysticercosis
US11739137B2 (en) Single domain antibodies to SARS-CoV-2 nucleocapsid protein
FI120376B (fi) Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
FI120349B (fi) Menetelmä fuusiopolypeptidin valmistamiseksi
Liu et al. Bispecific monoclonal antibodies against a viral and an enzyme: utilities in ultrasensitive virus ELISA and phage display technology
CN115850454B (zh) 抗柯萨奇病毒a16型的抗体及其制备方法和应用
CN115812078A (zh) 抗人类免疫缺陷病毒-1抗体及其使用方法
Zhang et al. Mimotopes selected by biopanning with high-titer HIV-neutralizing antibodies in plasma from Chinese slow progressors
JPH04505621A (ja) Ｔリンパ球向性レトロウイルス単クローン抗体
RU2794141C2 (ru) Однодоменные наноантитела против шиповидного белка вируса SARS-CoV-2
Burciaga-Flores et al. A New Approach in DENV Diagnostic based on Linear Peptides Obtained by Phage Display
KR102218517B1 (ko) 단일클론항체 쌍을 이용한 지카 바이러스의 검출 방법
TWI532838B (zh) 蓖麻子毒素融合瘤細胞株、其單株抗體、及包含該單株抗體的免疫檢測試劑及套組
RU2380378C2 (ru) Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич
CN114437205A (zh) 抗冠状病毒抗体及其应用
Walker Harnessing the Antibody Response: Advancing Antibody Discovery and Vaccine Development
Sanders Filamentous Bacteriophage as a Functional Biomaterial for Biomarker-Based Diagnostics

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120376

Country of ref document: FI

MM Patent lapsed